The clinical performance is complex and often involves multi-systematic burden. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of IBD requires a combination of clinical performance, imaging inspection, laboratory testing and pathological evaluation.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. The treatment plans for the treatment and management of IBD accompanying biological agents need to be individualized, typically including multidimensional management, such as drug therapy, rehabilitation interventions, and regular follow-up. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat infectious respiratory digestive endocrine disorders have been significantly improved.
Treatment requires close monitoring of therapeutic effects and adverse reactions, adapting to timely schemes according to changes in disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of IBD-associated biologics. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.